Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.

OBJECTIVE To identify novel polymorphisms in the solute carrier SLC22A16 gene and determine their influence on the pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients. METHODS SLC22A16 coding regions were screened in a total of 400 healthy subjects belonging to three distinct Asian ethnic groups (Chinese [n = 100], Malays [n = 100] and Indians [n = 100]) and in the Caucasian population (n = 100). Pharmacokinetic parameters of doxorubicin and doxorubicinol were estimated in Asian breast cancer patients undergoing adjuvant chemotherapy to investigate genotype-phenotype correlations. RESULTS Four novel polymorphisms (c.146A>G [exon 2], c.312T>C, c.755T>C [exon 4] and c.1226T>C [exon 5]) were identified. The genotypic frequency of the homozygous c.146GG polymorphism was approximately twofold higher in the healthy Chinese (13%) & Malay (18%) populations compared with the Indian (7%) and Caucasian (9%) populations. The genotypic frequency of the c.1226T>C polymorphism was observed to be significantly higher among the Caucasian (11%) and Indian (8%) study subjects compared with the Chinese (1%) and Malay (1%) ethnic groups (p < 0.005 in each case). Breast cancer patients harboring the 146GG genotype showed a trend towards higher exposure levels to doxorubicin (AUC(0 negative infinity)/dose/body surface area [BSA] [hm(-5)]: 21.6; range: 18.8-27.7) compared with patients with either the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 17.4; range: 8.2-26.3, p = 0.066) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 15.4; range: 6.2-38.0, p = 0.055). The exposure levels of doxorubicinol were also higher in patients harboring the variant 146GG genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 13.3; range: 8.8-21.7) when compared with patients harboring the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]): 9.8; range: 6.1-24.3, p = 0.137) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 8.98; range: 3.7-20.6, p = 0.047). CONCLUSION Among the four novel SLC22A16 polymorphisms identified, the c.146A>G and c.1226T>C polymorphisms exhibited interethnic variations in allele and genotype frequencies. This exploratory study suggests that the c.146A>G variation could contribute to the variations in the pharmacokinetics of doxorubicin and doxorubicinol in Asian cancer patients. Further in vitro studies are required to determine the functional impact of these novel polymorphisms on doxorubicin pharmacokinetics in cancer patients.

[1]  Xin Lu,et al.  Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. , 2002, Experimental hematology.

[2]  P. Johnston,et al.  The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites , 2005, Molecular Cancer Therapeutics.

[3]  Munir Pirmohamed,et al.  Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.

[4]  W. J. Brown,et al.  Systemic carnitine deficiency--a treatable inherited lipid-storage disease presenting as Reye's syndrome. , 1980, The New England journal of medicine.

[5]  W. Walther,et al.  Reversal of ABC Transporter-Dependent Multidrug Resistance in Cancer , 2006 .

[6]  D. Keppler,et al.  Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6* , 2001, The Journal of Biological Chemistry.

[7]  Y. Awasthi,et al.  Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. , 2007, International journal of oncology.

[8]  C. Stanley,et al.  Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. , 1988, The New England journal of medicine.

[9]  T. Abe,et al.  Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. , 2005, Biochemical and biophysical research communications.

[10]  Wooin Lee,et al.  Transporters and renal drug elimination. , 2004, Annual review of pharmacology and toxicology.

[11]  B. McEwen,et al.  Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.

[12]  Balram Chowbay,et al.  Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients , 2006, Pharmacogenetics and genomics.

[13]  M. Elisaf,et al.  Effect of L-Carnitine Supplementation on Lipid Parameters in Hemodialysis Patients , 1998, American Journal of Nephrology.

[14]  C. Haanen,et al.  Clinical Pharmacokinetics of Doxorubicin , 1988, Clinical pharmacokinetics.

[15]  W. Hait,et al.  Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. , 2003, Cancer research.

[16]  T. Rebbeck,et al.  Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. , 2007, Blood.

[17]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[18]  H. Koepsell,et al.  The SLC22 drug transporter family , 2004, Pflügers Archiv.

[19]  S. Dimauro,et al.  Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. , 1982, The Journal of pediatrics.

[20]  H. Koepsell,et al.  Amino Acids Critical for Substrate Affinity of Rat Organic Cation Transporter 1 Line the Substrate Binding Region in a Model Derived from the Tertiary Structure of Lactose Permease , 2005, Molecular Pharmacology.

[21]  S. Nigam,et al.  Novel human cDNAs homologous to Drosophila Orct and mammalian carnitine transporters. , 2002, Biochemical and biophysical research communications.

[22]  K. Giacomini,et al.  Arginine 454 and lysine 370 are essential for the anion specificity of the organic anion transporter, rOAT3. , 2001, Biochemistry.

[23]  Jürgen Brockmöller,et al.  Pharmacogenetics-based therapeutic recommendations — ready for clinical practice? , 2005, Nature Reviews Drug Discovery.

[24]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[25]  Xin Wang,et al.  Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. , 2003, Molecular pharmacology.

[26]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[27]  M. Niemi,et al.  Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans , 2007, Pharmaceutical Research.

[28]  A. Enomoto,et al.  Molecular Identification of a Novel Carnitine Transporter Specific to Human Testis , 2002, The Journal of Biological Chemistry.

[29]  H. Lennernäs.  Intestinal drug absorption and bioavailability: beyond involvement of single transport function , 2003, The Journal of pharmacy and pharmacology.

[30]  W. Sadee,et al.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. , 2005, Cancer research.